OZAN CEM GULER^1,*, EZGI OYMAK², GOZDE YAZICI³, OZLEM OZKAYA AKAGUNDUZ⁴, OGUZ CETINAYAK⁵, PETEK ERPOLAT⁶, ATIL AKSOY⁷, MURSEL DUZOVA⁸, BERNA AKKUS YILDIRIM⁹, MERAL KURT¹⁰, EMINE CANYILMAZ¹¹, GULER YAVAS¹², SERAP AKYUREK¹³, DIDEM COLPAN OKSUZ¹⁴, ESRA KAYTAN SAGLAM¹⁵, OMUR KARAKOYUN CELIK¹⁶, ENIS OZYAR¹⁷, MUSTAFA CENGIZ³, CEM ONAL^1,2,12

Oncology Research, Vol.31, No.3, pp. 299-306, 2023, DOI:10.32604/or.2023.028840 - 22 May 2023

Abstract The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses. The median age of the entire cohort was 56 years (range: 26–87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and… More >

Vanita Noronha^*, Kumar Prabhash^*, Amit Joshi^*, Vijay Maruti Patil^*, Sanjay Talole^†, Dipti Nakti^*, Arvind Sahu^*, Srushti Shah^‡, Sarbani Ghosh-Laskar^§, Prachi S. Patil^¶, Shaesta A. Mehta^¶, Nirmala Jambhekar^#, Abhishek Mahajan^**, Nilendu Purandare^††

Oncology Research, Vol.23, No.4, pp. 183-195, 2015, DOI:10.3727/096504016X14537290676865

Abstract There are little data on the efficacy and safety of taxane/platinum with definitive radiotherapy (RT) for esophageal/GEJ cancer. This article is a retrospective analysis of patients who received weekly paclitaxel 50 mg/ m2 and carboplatin AUC 2 with radical definitive RT for locally advanced esophageal/GEJ cancer. Between February 2011 and July 2014, 179 patients were included. The median age was 54 years. Ninety-two percent of patients had squamous histology. Mean RT dose was 58.7 Gy in 32 fractions over 53 days, with mean of six chemotherapy cycles. Fifty-six percent of patients developed ³grade 3 acute… More >